Ultime notizie per EZGO Technologies (NASDAQ:EZGO) Azioni

EZGO Technologies

EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.

EZGO Technologies Ltd

Danaher Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" rel="noreferrer noopener">in the first quarter</a>.
Danaher reported second-quarter adjusted EPS of $1.88,&nbsp;down from $1.92 a year ago, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44917043/danaher-reports-first-quarter-2025-results" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Operating cash flow was $1.3 billion, and non-GAAP&nbsp;free cash flow was $1.1 billion.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/02/43945075/dan-loeb-adjusts-healthcare-holdings-danaher-stake-trimmed-as-thermo-fisher-gains-favor" rel="noreferrer noopener">Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor</a>
Rainer Blair, president and chief executive officer, stated, &#8220;Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-than-expected respiratory demand in our molecular diagnostics business.&#8221;
&#8220;While the macro backdrop has become more dynamic since the start of the year, it&#8217;s in times like these that Danaher&#8217;s positioning and capabilities truly stand out. We believe that the combination of our team&#8217;s DBS-driven execution, resilient portfolio and strong balance sheet will continue to differentiate Danaher in 2025 and beyond,&#8221; Blair added.
Biotechnology&nbsp;<a target="_blank" href="https://investors.danaher.com/image/Q1+2025+Danaher+Earnings+Presentation.pdf" rel="noreferrer noopener">sales</a>&nbsp;increased to $1.61 billion compared to $1.52 billion a year ago.
Sales in the Life Sciences segment fell from $1.75 billion to $1.68 billion, and diagnostic sales decreased marginally from $2.53 billion to $2.45 billion.
The adjusted operating margin reached 29.6%, down from 30.1% a year ago, surpassing the management estimate of around 26.5%.
Guidance:&nbsp;Danaher&nbsp;<a target="_blank" href="https://investors.danaher.com/image/Q1+2025+Earnings+Supplement.pdf" rel="noreferrer noopener">reaffirms</a>&nbsp;that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year.
For FY2025, Danaher initiated adjusted EPS guidance of $7.60 to $7.75 vs. the consensus of$7.68. The company said, &#8220;We wanted to make sure everyone had an anchor point and believe having an adjusted EPS guide provides more clarity.&#8221;
&#8220;We are in unusual times and think it&#8217;s best to be as transparent as possible,&#8221; the company added.
The company forecasts that 2025 bioprocessing core revenue will increase in the high single digits, compared to the prior expectation of +6% to +7%.
Cepheid 2025 respiratory revenues will be around&nbsp;$1.7 billion.
For the second quarter of 2025, Danaher anticipates core revenue growth in low-single digits year over year.
The company expects an adjusted operating profit margin of ~25.5% due to a sequential decline compared to Q1. This is primarily due to lower respiratory volume at Cepheid, one of the higher-margin businesses, and the operating leverage is meaningful.
Bioprocessing core revenue growth is expected to be 7% for Q2 2025 and fiscal year 2025.
Life Sciences core revenue is expected to decline in the low-single to mid-single digits in Q2 2025 and remain flat for the fiscal year 2025.
Diagnostics sales are expected to increase in the low single digits in Q2 2025 and remain flat to low single digits in fiscal year 2025.
Price Action:&nbsp;At last check on Tuesday, DHR stock was trading 4.08% higher at $192.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44910307/liberty-energys-momentum-carries-into-q2-as-jpmorgan-tracks-growing-supply-side-risks" target="_blank" rel="noreferrer noopener">Liberty Energy&#8217;s Momentum Carries Into Q2 As JPMorgan Tracks Growing Supply-Side Risks</a></li>
</ul>
Photo: Shutterstock

Earnings

Large Cap

News

Guidance

Health Care

Movers

Trading Ideas

General

Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Community West Bancshare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWBC#NASDAQ">CWBC</a>) with a Market Perform and lowers the price target from $21 to $19.

Price Target

Analyst Ratings

CWBC

Keefe, Bruyette & Woods Maintains Market Perform on Community West Bancshare, Lowers Price Target to $19

Wells Fargo analyst Michael Turrin maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Underweight and lowers the price target from $30 to $22.

Wells Fargo Maintains Underweight on RingCentral, Lowers Price Target to $22

Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Outperform and lowers the price target from $77 to $68.

Keefe, Bruyette & Woods Maintains Outperform on Comerica, Lowers Price Target to $68

MCRB

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Wells Fargo analyst Michael Turrin maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Overweight and lowers the price target from $940 to $700.

HUBS

Wells Fargo Maintains Overweight on HubSpot, Lowers Price Target to $700

JMP Securities analyst Andrew Boone reiterates ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) with a Market Outperform and maintains $66 price target.

Reiteration

JMP Securities Reiterates Market Outperform on ODDITY Tech, Maintains $66 Price Target

Keefe, Bruyette &amp; Woods analyst Chris O'Cull maintains Chemung Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHMG#NASDAQ">CHMG</a>) with a Market Perform and lowers the price target from $60 to $55.

CHMG

Keefe, Bruyette & Woods Maintains Market Perform on Chemung Financial, Lowers Price Target to $55

NUBURU, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>), a pioneering leader in high-power blue laser technology, announces a transformative strategic update underscoring its commitment to advancing into high-growth markets and is pleased to announce the company has secured funding partners to address up to approx. $3.4 million in accounts payables left from previous management, enabling NUBURU to eliminate past debts and enhance its financial flexibility.
This pivotal announcement comes on the heels of NUBURU's previous strategic investment in Supply@ME Capital Plc, a $5.15 million on-demand convertible funding commitment, which further positions the company to pivot towards a capital-light, sustainable growth approach through innovative fintech solutions. The integration of SYME's financial platform will provide liquidity and empower NUBURU to maintain competitive inventory levels as it braces for exciting growth in the defense and security sectors.

Financing

BURU

NUBURU Secures Funding Partners To Address Up To ~$3.4M In Accounts Payables Left From Previous Management, Enabling Co To Eliminate Past Debts And Enhance Its Financial Flexibility

JMP Securities analyst Brian McKenna reiterates FTAI Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIP#NASDAQ">FIP</a>) with a Market Outperform and maintains $12 price target.

JMP Securities Reiterates Market Outperform on FTAI Infrastructure, Maintains $12 Price Target

Wells Fargo analyst Michael Turrin maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Overweight and lowers the price target from $85 to $65.

GTLB

Wells Fargo Maintains Overweight on GitLab, Lowers Price Target to $65

While Washington throws punches <a href="https://www.benzinga.com/topic/semiconductors">and semiconductor companies</a> grab headlines, Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google is playing the long game in near silence.
JPMorgan analyst Doug Anmuth isn&#8217;t buying the doom and gloom. He's still Overweight on Alphabet, setting a $180 price target by December 2025 for the stock. He sees a future where Google&#8217;s GenAI innovation does the heavy lifting even if macro winds blow rough.
Sure, there's plenty to stress over: "macro and tariff-related concerns," a bruising antitrust loss in the AdTech trial and OpenAI's 800M+ user rocket ship. Anmuth trimmed estimates across the board, even conceding Google&#8217;s reported Search growth this year to a "hopefully-too-punitive 3%." But that's just the headline drama.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/44910668/goog-stock-losing-streak-potential-reversal">Options Corner: Monday Blues Can&#8217;t Hide Alphabet Stock&#8217;s Potential Upside Pivot</a>
<h2 class="wp-block-heading">AI Push Continues Despite Macro Noise</h2>
Under the radar, Google&#8217;s AI machine is quietly cranking up. "We are encouraged by Google&#8217;s GenAI innovation," Anmuth said, noting a flurry of product updates that are putting serious pressure on competitors. Gemini 2.5 Pro, the new Flash model and Veo 2 for video generation are not just fancy toys &#8211; they&#8217;re signs of an ecosystem shift.
Anmuth sees the groundwork being laid for something bigger: "We remain optimistic about Google&#8217;s advances in GenAI with an accelerated pace of innovation this year." With 15 Google products crossing 500 million users &#8211; seven of which top two billion &#8211; Gemini&#8217;s reach is everywhere.
&#8220;The GenAI opportunity is too significant for Google to pull back on &amp; GenAI workloads&nbsp;could&nbsp;help mitigate macro pressures,&#8221; he said. The $75B capex guide for 2025 is a clear tell that Google isn't slowing down.
<h2 class="wp-block-heading">Cloud Momentum Still Healthy</h2>
Cloud is another big bet. Fresh off a star turn at the Google Cloud Next conference, Google is positioning itself as the CSP (cloud service provider) of choice for GenAI. Anmuth was impressed by "AI optimization with leading price performance, precision, &amp; quality" and says Google's interoperability strategy and foundational model portfolio could win over more business clients.
The analyst is also betting that key events, such as Google I/O, Marketing Live and Made by Google, will keep the GenAI narrative front and center. "We expect upcoming product-focused events to emphasize consumer and advertiser use cases &amp; further advance Google's GenAI narrative," Anmuth wrote.
<h2 class="wp-block-heading">Legal Clouds Loom, But No Thunder Yet</h2>
And what about the legal drama? 
Anmuth sees the AdTech ruling as a known risk: "An unfavorable AdTech outcome was mostly anticipated by investors," and the bigger worry remains the search trial remedy due by August. But even with Network revenue declining 3% this year, Anmuth isn't rattled.
Google's search crown may look a little wobbly from afar, but its AI engine is humming beneath the surface. 
As Anmuth puts it, "The GenAI opportunity is too significant for Google to pull back on."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44909414/google-parent-alphabets-topline-can-withstand-pressure-in-uncertain-macro-scenario-compared-to-peers-analyst">Google Parent Alphabet&#8217;s Topline Can Withstand Pressure In Uncertain Macro Scenario Compared To Peers: Analyst</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Tech

GOOG

GOOGL

Alphabet's $75 Billion Bet: 'Too Significant For Google To Pull Back' Now, Says JPMorgan

Keefe, Bruyette &amp; Woods analyst Michael Brown maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Market Perform and lowers the price target from $141 to $139.

Keefe, Bruyette & Woods Maintains Market Perform on Blackstone, Lowers Price Target to $139

Chevron CEO Wirth Says Reaction To Trade Issues Has Led To Expectation Of Reduced Oil Demand

Evercore ISI Group analyst Jonathan Chappell maintains TORM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) with a Outperform and lowers the price target from $25 to $23.

TRMD

Evercore ISI Group Maintains Outperform on TORM, Lowers Price Target to $23

Wells Fargo analyst Michael Turrin maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Equal-Weight and lowers the price target from $45 to $23.

FIVN

Wells Fargo Maintains Equal-Weight on Five9, Lowers Price Target to $23

Evercore ISI Group analyst Jonathan Chappell maintains Teekay Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) with a Outperform and lowers the price target from $53 to $51.

Evercore ISI Group Maintains Outperform on Teekay Tankers, Lowers Price Target to $51

Evercore ISI Group analyst Jonathan Chappell maintains Scorpio Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STNG#NYSE">STNG</a>) with a Outperform and lowers the price target from $64 to $60.

STNG

Evercore ISI Group Maintains Outperform on Scorpio Tankers, Lowers Price Target to $60

Wells Fargo analyst Michael Turrin maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Underweight and lowers the price target from $73 to $65.

DOCU

Wells Fargo Maintains Underweight on Docusign, Lowers Price Target to $65

SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-endoxifen as well as methods of treating subjects with those oral formulations.
This newly granted patent further fortifies Atossa's intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, encompassing novel compositions and methods related to (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator (SERM). Specifically, the patent covers enteric oral formulations of (Z)-endoxifen and salts thereof as well as their use in treating hormone-dependent breast and reproductive tract disorders.

ATOS

Atossa Therapeutics: USPTO Grants New Patent Directed To Enteric Oral Formulations Comprising (Z)-endoxifen As Well As Methods Of Treating Subjects With Oral Formulations

Comments

EZGO Technologies

Notizie

Ultime notizie per EZGO Technologies (NASDAQ:EZGO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO